Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.63M Sell
9,868
-331
-3% -$89.6K 0.01% 785
2025
Q4
$2.56M Buy
10,199
+1,185
+13% +$315K 0.01% 744
2025
Q3
$2.59M Buy
9,014
+125
+1% +$33.5K 0.02% 648
2025
Q2
$2.33M Buy
8,889
+1,582
+22% +$385K 0.02% 606
2025
Q1
$1.68M Buy
7,307
+651
+10% +$158K 0.02% 610
2024
Q4
$1.53M Buy
6,656
+1,140
+21% +$262K 0.02% 593
2024
Q3
$1.23M Buy
5,516
+3,166
+135% +$696K 0.02% 491
2024
Q2
$478K Buy
+2,350
New +$478K 0.02% 558

Other funds holding LH

&Partners's LH Position: Q1 2026 in Review

&Partners reduced its Labcorp (LH) stake by 3.2% in Q1 2026, selling an estimated $89.6K and leaving 9,868 shares worth $2.63M. The position accounts for 0.01% of the portfolio, ranked #785.

&Partners first reported a position in LH in Q2 2024 and has held it in 8 quarters since. 1,031 funds tracked by Wall St. Rank hold LH as of Q1 2026.

  • &Partners held 9,868 shares of Labcorp worth $2.63M as of Q1 2026.
  • &Partners sold 331 Labcorp shares in Q1 2026, an estimated $89.6K.
  • Labcorp made up 0.01% of &Partners's portfolio in Q1 2026, its #785 holding.
  • &Partners first reported a position in Labcorp in Q2 2024 and has held it in 8 quarters since.
  • 1,031 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.